Clearpoint Neuro Inc（CLPT）财务数据CLPTClearpoint Neuro Inc

Clearpoint Neuro Inc (CLPT) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Products: Functional neurosurgery, accounting for 37.2% of total sales, equivalent to $3.43M. Other significant revenue streams include Services: Biologics and drug delivery and Products: Biologics and drug delivery. Understanding this composition is critical for investors evaluating how CLPT navigates market cycles within the Advanced Medical Equipment & Technology industry.

Evaluating the bottom line, Clearpoint Neuro Inc maintains a gross margin of 58.46%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -52.44%, while the net margin is -61.78%. These profitability ratios, combined with a Return on Equity (ROE) of -167.52%, provide a clear picture of how effectively CLPT converts its operational activities into shareholder value.

In the context of the broader market, CLPT competes directly with industry leaders such as PROF and MOBI. With a market capitalization of $325.63M, it holds a significant position in the sector. When comparing efficiency, CLPT's gross margin of 58.46% stands against PROF's 78.41% and MOBI's 83.21%. Such benchmarking helps identify whether Clearpoint Neuro Inc is trading at a premium or discount relative to its financial performance.

ClearPoint has shown revenue growth, with Q2 2026 revenue at $10.9 million, up 18% year-over-year. However, net income remains negative, with a loss of -$7.46 million in Q3 2026. Gross margin is healthy at 62%, but the company is facing a significant operational cash burn.